ArticleHearing research2025
Promotion of a new gap junction gene Cx46 (GJA3) expression in the cochlea after Cx26 (GJB2) deficiency.
Article in Hearing research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Upregulation of ATP-purinergic P2×2 receptors in the cochlea over-amplifies hearing sensitivity leading to hyperacusis and attenuation by antagonists.bioRxiv : the preprint server for biology · 2026Article
Corrections and comments
- Update of
Authors and funding
5 authors.
Funding
Abstract
Gap junction GJB2 (connexin 26, Cx26) gene mutations are responsible for >50 % of nonsyndromic hearing loss. The pathological changes mainly locate in the cochlea. However, little is known about genetic changes in the cochlea after Cx26 deficiency. In this study, we employed bulk Poly(A) RNA-Seq technique and found that Cx26 deficiency could cause many genes up- and down-regulated in the cochlea. One of the unexpected findings is significant upregulation of a gap junctional gene GJA3 (Cx46), which normally expresses in the eye rather than the ear. Quantitative PCR and digital droplet PCR further confirmed the promotion of Cx46 expression in the cochlea after Cx26 deficiency. Immunofluorescent staining showed that the promoted Cx46 was expressed at the same location as Cx26 expression in the cochlea and integrated into the same gap junctional plaques. This promotion is Cx26-specific; there was no promotion of Cx46 expression in the cochlea after knockout (KO) of Cx30 (GJB6), which is another predominant connexin co-expressed in the cochlea. Gene Set Enrichment Analysis (GSEA) revealed that Cx26 deficiency but not Cx30 KO upregulated a phototransduction pathway to promote the eye-specific gene Cx46 expression in the cochlea. This may present a natural compensation to the loss of Cx26 function, since both Cx26 and Cx46 have similar channel properties. Our findings also provide a new cue for developing a genetic approach to treat this common hereditary deafness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.